u/burned_once_twice

take it. if my £90 mistake stops one person storing a mixed vial in the door it was cheaper than most lessons i have paid for.

i have gone back and reread our thread with that in mind and i do not love what i found.

can confirm, it was mine, and it cost me a vial and a great deal of dignity.

it was reconstituted. week one. edit: oh. oh no. so this is very possibly forty-two days of a mixed vial in the warmest part of a bad fridge.

"an organiser who is drowning will spend the remaining money on the loudest complainants" is the most useful sentence anyone has said to me about this in two years.

The confounding problem, stated plainly, because this board keeps stepping on it.

Substantial weight loss moves lipids, liver enzymes, insulin sensitivity markers and several others in its own right. If you are losing weight while taking something, any change in those markers has at least two candidate explanations and you cannot separate them from your own panel.

What you can do is standardise, take a baseline, keep the series long, and be honest in your posts about what is and is not attributable. The threads that say "this compound did X to my ApoB" almost never have the design to support the claim, mine included.

after losing £340 to a group buy i now weight reship policy above price and roughly level with purity. it is the only thing that protects you from the failure mode that actually happens.

after the group buy i overcorrected into being extremely careful about accusations. turns out that is just the correct amount of careful.

Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board.

Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.

number five cost me £340. no escrow, no group buy. i will keep saying it until it is boring and then i will keep saying it after that.

completely fine with that. i want three things and i want them to arrive.

yeah. the lane table is a public good and i did not appreciate that until i needed it.

ask what the beyond-use date is based on

salt forms are the recurring argument and the answer is boring

Is that the 48-week figure or an earlier readout?

Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

What do you think the glucagon component is adding, specifically?

Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.

Different laboratories use different assay platforms with different calibration. Comparing across labs adds a systematic offset that is invisible on the report.

Why this board exists, stated once, since new members find it and are surprised.

Every other community surface on this site is a record of things that worked, because people post when they have something to show. That produces an archive with a systematic bias, and somebody at week three reads it and concludes that their difficult month is unusual.

This board is the counterweight. The rule is that nobody gets judged, that corrections stay up, and that the failures are written down with the same care as the successes. It is the least-visited part of the site and the part I would keep if I could only keep one.

Same. The thing that went wrong for me was procedural and boring and it cost me a lot.

Yes — log what happened rather than what you intended. My retrospective entries were quietly wrong every time.

Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.

Left up, flaired Correction. The original stays with it — that is how this board works.

Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.

Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.

Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running. Everything else is inference.

Why contemporaneous beats reconstructed, with the failure mode.

Memory smooths. Reconstructing a fortnight from recollection produces a series that is more regular, more consistent with your current beliefs, and quietly wrong in a direction that flatters the story you are already telling.

I found this out by reconstructing six weeks and later finding order receipts that contradicted my own entries. The log was not a little wrong; it was wrong in exactly the direction that made my narrative work. Write it down on the day, even the boring days, especially the boring days.

How long have you been logging?

research-use-only material is not approved for human use, full stop

Correction: that marker is reported in different units by different labs, which explains the tenfold difference you are seeing.

Name removed. The rule holds here too: no individuals, no accusations without documents.

Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

I would not draw a trend line through that. Two points and a gap is not a series.